# Ofev® (nintedanib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nintedanib

> The PDUFA target action date for Ofev® (nintedanib), sponsored by Avalyn Pharma Inc. (AVLN), is April 26, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, half-year only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Ofev® (nintedanib) PDUFA date?

The PDUFA target action date for Ofev® (nintedanib), sponsored by Avalyn Pharma Inc. (AVLN), is April 26, 2027. Status: scheduled. SEC Form 10-Q: "In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027." Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/nintedanib)

Source: SEC Form 10-Q, accession 0001082554-26-000035, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/nintedanib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ofev® (nintedanib) |
| Codes | MNKD-201 |
| Sponsor | Avalyn Pharma Inc. (AVLN) https://sec-api.dev/companies/avln/catalysts |
| Indications | [idiopathic pulmonary fibrosis](https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis) |
| Modality | small_molecule |
| FDA designations | fast track |

## Timeline

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-13, last confirmed 2025-03-17.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040232): ""In parallel, we expect to share topline data from our pivotal Phase 3 trial in CHB-associated liver fibrosis in the second quarter of 2025, which will help inform our U.S. Phase 2 proof-of-concept trial of F351 in MASH-associated liver fibrosis."" https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-040232): "In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by Q2 2025." https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125869): "In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by early 2025." https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-ex99_1.htm

### late 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-08-25, last confirmed 2025-08-25.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-186994): "In addition to established marketed products, MannKind is advancing a late-stage pipeline that includes Inhaled Clofazimine (MNKD-101), which is currently in a phase 3 global study for nontuberculous mycobacterial (NTM) lung disease, and nintedanib DPI (MNKD-201), which is expected to initiate a phase 2 clinical trial for IPF by year-end 2025." https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701dex991.htm

### 1H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-280149): "Following the positive Phase 2a RIVER trial results earlier this year, the Company is planning to initiate a Phase 2b RCC study in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/trvi-ex99_1.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-02-26, last confirmed 2026-05-06.
- SEC Form 10-Q (accession 0001193125-26-208916): "We are currently conducting a Phase 1b study of MNKD-201 in the United States, with top line data expected in the third quarter of 2026, as well as a global Phase 2 study to assess the potential safety and efficacy of this investigational product in patients with IPF, in which we expect the first patient to be enrolled in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/899460/000119312526208916/mnkd-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073516): "We are currently conducting a Phase 1b study of MNKD-201 in the United States, top line data expected in early 2H 2026, as well as a global Phase 2 study to assess the potential safety and efficacy of this investigational product in patients with IPF, in which we expect the first patient to be enrolled in in Q2 2026." https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-208910): "Completed enrollment of Cohort 1 in Phase 1b (INFLO-1) study with no discontinuations or serious adverse events in patients with idiopathic pulmonary fibrosis (IPF); topline data expected in Q3 2026" https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073509): "Enrollment underway in Phase 1b (INFLO-1) study, top line data expected in 2H 2026" https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-073516): "6 study of MNKD-201 in the United States, top line data expected in early 2H 2026, as well as a global Phase 2 study to assess the potential safety and efficacy of this investigational product in patients with IPF, in which we expect the first patient to be enrolled in in Q2 2026." https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm

### Sep 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001082554-26-000035): "In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-06-03, last confirmed 2026-08-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345807): "the expected initiation of a Phase 1 trial of AP03 by the end of 2026, the interpretation and potential implications of clinical data" https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-254581): "the planned initiation of a Phase 1 trial of AP03 by the end of 2026" https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/ck0001540171-ex99_1.htm

### April 26, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001082554-26-000035): "In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm

### late 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: idiopathic pulmonary fibrosis.
- First seen 2026-04-08, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457053): "the ongoing enrollment in the AURA Phase 2 trial of AP02 in patients with IPF, including the planned enrollment of 160 patients, and the expected timing of topline data in late 2027" https://www.sec.gov/Archives/edgar/data/1540171/000119312526457053/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-254581): "Enrollment underway in AURA Phase 2 trial of AP02 in patients with idiopathic pulmonary fibrosis (IPF) with topline data anticipated by the end of 2027" https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/ck0001540171-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-197686): "A global Phase 2 clinical program has been initiated, with a data readout expected in late 2027." https://www.sec.gov/Archives/edgar/data/1540171/000119312526197686/424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-147573): "A global Phase 2 clinical program has been initiated, with a data readout expected in late 2027." https://www.sec.gov/Archives/edgar/data/1540171/000119312526147573/ck0001540171-20260408.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457053): "These forward-looking statements include, without limitation, implied and express statements about Avalyn's beliefs and expectations regarding: topline data from the MIST Phase 2b trial of AP01 in patients with PPF expected in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1540171/000119312526457053/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345807): "Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-273405): "These forward-looking statements include, without limitation, implied and express statements about Avalyn's beliefs and expectations regarding the possibility that additional patients may be enrolled in the Phase 2b MIST trial, the timing of topline 12-month clinical results in the Phase 2b MIST clinical trial of AP01 in the second half of 2027; the interpretation and significance of the Phase 2b MIST trial and Phase 1b ATLAS clinical data; and the therapeutic potential of its product candidates." https://www.sec.gov/Archives/edgar/data/1540171/000119312526273405/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345807): "Topline data are anticipated in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345807): "Topline data are anticipated in late 2027." https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-345807): "These forward-looking statements include, without limitation, implied and express statements about Avalyn's beliefs and expectations regarding: topline data readout for MIST expected in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-273405): "Company expects to report topline 12-month clinical results in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1540171/000119312526273405/ck0001540171-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-273405): "We expect MIST to help inform the full impact of AP01 on preserving lung function and improving quality of life for people living with PPF, and we look forward to reporting topline data in the second half of 2027."" https://www.sec.gov/Archives/edgar/data/1540171/000119312526273405/ck0001540171-ex99_1.htm

## Same indication

- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [LTI-03](https://sec-api.dev/pdufa/lti-03) (RNTX)
- [LTSE-2578](https://sec-api.dev/pdufa/ltse-2578) (GPCR)
- [TTI-101](https://sec-api.dev/pdufa/tti-101) (TVRD)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nintedanib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ofev® (nintedanib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nintedanib

```bibtex
@misc{secapidev_pdufa_nintedanib_20261116,
  title        = {Ofev® (nintedanib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nintedanib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nintedanib_20261116","title":"Ofev® (nintedanib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nintedanib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
